Plasmodium falciparum FIKK 9.1 kinase modeling to screen and identify potent antimalarial agents from chemical library
The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite...
Saved in:
Published in: | 3 Biotech Vol. 13; no. 8; p. 277 |
---|---|
Main Authors: | , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Cham
Springer International Publishing
01-08-2023
Springer Nature B.V |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite’s proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC
50
of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC
50
of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant (
K
d
) is measured to be 27.8 ± 2.07 μM with a stoichiometry of
n
= 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials. |
---|---|
AbstractList | The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite’s proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC50 of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC50 of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant (Kd) is measured to be 27.8 ± 2.07 μM with a stoichiometry of n = 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials. The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite's proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC50 of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC50 of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant (Kd) is measured to be 27.8 ± 2.07 μM with a stoichiometry of n = 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials.The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite's proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC50 of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC50 of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant (Kd) is measured to be 27.8 ± 2.07 μM with a stoichiometry of n = 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials.The online version contains supplementary material available at 10.1007/s13205-023-03677-x.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13205-023-03677-x. The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite’s proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC 50 of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC 50 of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant ( K d ) is measured to be 27.8 ± 2.07 μM with a stoichiometry of n = 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials. The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing kinases. FIKK9.1 kinase is considered as an essential protein for parasite survival. It is localized in major organelles present in parasite and trafficked throughout the infected RBC. It is speculated that FIKK9.1 may phosphorylate several substrates in the parasite's proteome and contribute to parasite survival. Therefore, FIKK9.1 is an attractive target that may lead to a novel class of antimalarials. To identify specific FIKK9.1 kinase inhibitors, we virtually screened organic structural scaffolds from a library of 623 entries. The top hits were identified based on conformations and molecular interactions with the ATP biophore. The hits were also validated under in vitro conditions. In this study, we identified seven top hit organic compounds that may arrest the growth of parasites by inhibiting FIKK9.1 kinase. Evaluation of top hit compounds in antimalarial activity assay identifies that the highly substituted 1,3-selenazolidin-2-imine 1 and thiophene 2 are inhibiting parasite growth with an IC of 3.2 ± 0.27 μg/ml and 3.13 ± 0.16 μg/ml, respectively. These functionalized heterocyclic compounds 1 and 2 kills the malaria parasite with an IC of 2.68 ± 0.02 μg/ml and 3.08 ± 0.14 μg/ml, respectively. Isothermal titration calorimetry analysis indicate that ATP is binding to the FIKK9.1 kinase. The dissociation constant ( ) is measured to be 27.8 ± 2.07 μM with a stoichiometry of = 1. The heterocyclic scaffolds 1 and 2 were abolishing the binding of ATP into the binding pocket. They in-turn reduce the ability of FIKK9.1 kinase to phosphorylate its substrate. Our study found that compounds 1 and 2 are potent inhibitor of FIKK9.1 kinase and the inhibition of FIKK9.1 kinase using small molecules disturbs the parasite life cycle and leads to the death of parasites. This provides new insight in development of novel antimalarials. The online version contains supplementary material available at 10.1007/s13205-023-03677-x. |
ArticleNumber | 277 |
Author | Punniyamurthy, Tharmalingam Kumar, D. Anil Karjee, Pallab Trivedi, Vishal Prasad, M. Rajendra |
Author_xml | – sequence: 1 givenname: D. Anil surname: Kumar fullname: Kumar, D. Anil organization: Malaria Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati – sequence: 2 givenname: Pallab surname: Karjee fullname: Karjee, Pallab organization: Department of Chemistry, Indian Institute of Technology Guwahati – sequence: 3 givenname: M. Rajendra surname: Prasad fullname: Prasad, M. Rajendra organization: Malaria Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati – sequence: 4 givenname: Tharmalingam surname: Punniyamurthy fullname: Punniyamurthy, Tharmalingam organization: Department of Chemistry, Indian Institute of Technology Guwahati – sequence: 5 givenname: Vishal orcidid: 0000-0003-2520-6083 surname: Trivedi fullname: Trivedi, Vishal email: vtrivedi@iitg.ernet.in, Vishalash_1999@yahoo.com organization: Malaria Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37476548$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1vFDEMhiNUREvpH-CAInHhMiWfm8wJoYpC1UpwAIlb5E0y25SZZElmq-6_x2XL8nEgl1j249e23qfkIJccCXnO2SlnzLxuXAqmOyZkx-TCmO7uETkSvGedNtIe7GPx9ZCctHbD8Gmue86ekENplFloZY_I7acR2lRC2kx0gNGnNVQMzy8uL2l_yum3lKFFikQcU17RudDma4yZQg40hZjnNGzpuswYYW5OE4xQE4wUVphqdKhlov46TsljckzLCnX7jDzGaS2ePPzH5Mv5u89nH7qrj-8vzt5edV6JxdzZyJU0EgYTg_U-iqh5EAp09CAGrmwf2LCwKoDA84zRPoCSg4flUkMYtDwmb3a6681yisHjRhVGt664Zt26Asn9Xcnp2q3KreNMaiX5vcKrB4Vavm9im92Umo_jCDmWTXPCKo4mWM4RffkPelM2NeN9SMleWml7gZTYUb6W1moc9ttw5u6tdTtrHaq6n9a6O2x68ecd-5ZfRiIgd0DDUl7F-nv2f2R_AMO7s7M |
Cites_doi | 10.1186/s12936-016-1408-1 10.1186/1471-2164-5-79 10.1093/trstmh/tru101 10.1038/nrmicro.2017.161 10.1056/NEJMc1713777 10.1371/journal.pone.0011747 10.1021/jm501603h 10.2174/1570180815666180727121200 10.1038/ncomms16044 10.1021/acsomega.7b00997 10.1016/j.bbrc.2020.05.154 10.1038/s41564-020-0702-4 10.1111/j.1742-4658.2007.05997.x 10.1111/j.1365-2141.2011.08755.x 10.3390/tropicalmed4010026 10.1111/bjh.16219 10.1016/j.bioorg.2017.09.011 10.1182/blood-2014-06-583054 10.1021/acsinfecdis.0c00724 10.1101/cshperspect.a025619 |
ContentType | Journal Article |
Copyright | King Abdulaziz City for Science and Technology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
Copyright_xml | – notice: King Abdulaziz City for Science and Technology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
DBID | NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1007/s13205-023-03677-x |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Economics Chemistry Agriculture |
EISSN | 2190-5738 |
ExternalDocumentID | 10_1007_s13205_023_03677_x 37476548 |
Genre | Journal Article |
GroupedDBID | -A0 -EM 0R~ 2VQ 4.4 406 40G 8AO 8FE 8FG 8FH AAAVM AAFGU AAHNG AANZL AAPBV AATNV AATVU AAUYE AAYFA ABDBF ABDZT ABECU ABFGW ABFTV ABJCF ABJNI ABJOX ABKAS ABKCH ABMQK ABSXP ABTEG ABTKH ABTMW ABXPI ACBMV ACBRV ACBYP ACGFS ACHSB ACIGE ACIPQ ACIWK ACMLO ACOKC ACPRK ACTTH ACVWB ACWMK ADBBV ADDVE ADHHG ADINQ ADKNI ADKPE ADMDM ADOXG ADRAZ ADTPH ADURQ ADYFF ADZKW AEFTE AEGXH AEJRE AENEX AEOHA AEPYU AESKC AESTI AEVLU AEVTX AEXYK AFGXO AFKRA AFNRJ AFQWF AGDGC AGGBP AGJBK AGMZJ AHBYD AHSBF AHYZX AIAKS AILAN AIMYW AITGF AJDOV AJRNO AJZVZ AKQUC ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AMXSW AMYLF AMYQR AOIJS AXYYD BBNVY BENPR BGLVJ BGNMA BHPHI C24 C6C CCPQU CSCUP DNIVK DPUIP EBLON EBS EIOEI EJD FERAY FFXSO FINBP FNLPD FSGXE GGCAI GJIRD GX1 H4N HCIFZ HYE HZ~ IKXTQ IWAJR J-C JZLTJ KOV KQ8 L6V LK8 LLZTM M48 M4Y M7P M7S M~E NPVJJ NQJWS NU0 O9- O9J OK1 PT4 PTHSS RNS RPM RSV SCM SISQX SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW STPWE TSG U2A UOJIU UTJUX UZXMN VFIZW Z5O Z7U Z7V Z7W Z7Y Z7Z Z83 ZMTXR 53G AACDK AAHBH AAJBT AASML ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU FIGPU NPM ROL SJYHP AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c426t-8e14373af7ed8cce2e51d24a5eca2f1489d0f684da2000775cda43fcabb5adf53 |
IEDL.DBID | RPM |
ISSN | 2190-572X |
IngestDate | Tue Sep 17 21:28:51 EDT 2024 Sat Oct 26 04:30:59 EDT 2024 Thu Oct 10 16:46:23 EDT 2024 Thu Nov 21 22:56:56 EST 2024 Sat Nov 02 12:29:51 EDT 2024 Sat Dec 16 12:04:40 EST 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Malaria Lead identification and antimalarial FIKK kinase |
Language | English |
License | King Abdulaziz City for Science and Technology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c426t-8e14373af7ed8cce2e51d24a5eca2f1489d0f684da2000775cda43fcabb5adf53 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-2520-6083 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354315 |
PMID | 37476548 |
PQID | 2839383892 |
PQPubID | 2034528 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10354315 proquest_miscellaneous_2841023811 proquest_journals_2839383892 crossref_primary_10_1007_s13205_023_03677_x pubmed_primary_37476548 springer_journals_10_1007_s13205_023_03677_x |
PublicationCentury | 2000 |
PublicationDate | 2023-08-01 |
PublicationDateYYYYMMDD | 2023-08-01 |
PublicationDate_xml | – month: 08 year: 2023 text: 2023-08-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: Germany – name: Heidelberg |
PublicationTitle | 3 Biotech |
PublicationTitleAbbrev | 3 Biotech |
PublicationTitleAlternate | 3 Biotech |
PublicationYear | 2023 |
Publisher | Springer International Publishing Springer Nature B.V |
Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
References | NunesMCPlasmodium falciparum FIKK kinase members target distinct components of the erythrocyte membranePLoS One20105710.1371/journal.pone.0011747206685262909202 Arendse LB et al (2021) Plasmodium kinases as potential drug targets for malaria: challenges and opportunities. ACS Infect Dis MnzavaAPMalaria vector control at a crossroads: public health entomology and the drive to eliminationTrans R Soc Trop Med Hyg2014108955055410.1093/trstmh/tru10125009173 BalajiSNSahasrabuddheAATrivediVInsulin signalling in RBC is responsible for growth stimulation of malaria parasite in diabetes patientsBiochem Biophys Res Commun202052835315371:CAS:528:DC%2BB3cXhtFSlu7nO10.1016/j.bbrc.2020.05.15432505351 LinBCFIKK Kinase, a Ser/Thr kinase important to malaria parasites, is inhibited by tyrosine kinase inhibitorsACS Omega2017210660566121:CAS:528:DC%2BC2sXhs1alur%2FE10.1021/acsomega.7b00997300235256044879 BatinovicSAn exported protein-interacting complex involved in the trafficking of virulence determinants in Plasmodium-infected erythrocytesNat Commun20178160441:CAS:528:DC%2BC2sXhtFClsbbP10.1038/ncomms16044286917085508133 WardPProtein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryoteBMC Genom200457910.1186/1471-2164-5-79 Nsanzabana C (2019) Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis 4(1). Menard D, Dondorp A (2017) Antimalarial drug resistance: a threat to malaria elimination. Cold Spring Harb Perspect Med 7(7). VimeeRVirtual screening, molecular modelling and biochemical studies to exploit PF14_0660 as a target to identify novel anti-malarialsLett Drug Des Discov201916441742610.2174/1570180815666180727121200 Pousibet-PuertoJImpact of using artemisinin-based combination therapy (ACT) in the treatment of uncomplicated malaria from Plasmodium falciparum in a non-endemic zoneMalar J201615133910.1186/s12936-016-1408-1273681604930579 AK D et al (2021) Plasmodium falciparum FIKK9.1 is a monomeric serine-threonine protein kinase with features to exploit as a drug target. Chem Biol Drug Des. HaldarKBhattacharjeeSSafeukuiIDrug resistance in PlasmodiumNat Rev Microbiol20181631561701:CAS:528:DC%2BC1cXhtl2msro%3D10.1038/nrmicro.2017.161293558526371404 DasSEvidence of artemisinin-resistant Plasmodium falciparum malaria in Eastern IndiaN Engl J Med2018379201962196410.1056/NEJMc171377730428283 MoxonCAGrauGECraigAGMalaria: modification of the red blood cell and consequences in the human hostBr J Haematol201115466706791:CAS:528:DC%2BC3MXhtlSks7rF10.1111/j.1365-2141.2011.08755.x216237673557659 TutejaRMalaria—an overviewFEBS J200727418467046791:CAS:528:DC%2BD2sXhtVyksL3L10.1111/j.1742-4658.2007.05997.x17824953 SiddiquiGProellochsNICookeBMIdentification of essential exported Plasmodium falciparum protein kinases in malaria-infected red blood cellsBr J Haematol202018857747831:CAS:528:DC%2BB3cXjvVWnuro%3D10.1111/bjh.1621931650539 RugMExport of virulence proteins by malaria-infected erythrocytes involves remodeling of host actin cytoskeletonBlood201412423345934681:CAS:528:DC%2BC2cXitV2nsbbP10.1182/blood-2014-06-583054251393484246041 DaviesHAn exported kinase family mediates species-specific erythrocyte remodelling and virulence in human malariaNat Microbiol2020568488631:CAS:528:DC%2BB3cXmvFymur4%3D10.1038/s41564-020-0702-4322845627116245 Organization W.H. (2020) World malaria report 2020: 20 years of global progress and challenges. LinBCThe anthraquinone emodin inhibits the non-exported FIKK kinase from Plasmodium falciparumBioorg Chem2017752172231:CAS:528:DC%2BC2sXhs1aktL3M10.1016/j.bioorg.2017.09.01128987877 VijayanRSConformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitorsJ Med Chem20155814664791:CAS:528:DC%2BC2cXitVCku7rP10.1021/jm501603h25478866 3677_CR13 3677_CR15 BC Lin (3677_CR9) 2017; 75 J Pousibet-Puerto (3677_CR16) 2016; 15 H Davies (3677_CR6) 2020; 5 3677_CR10 MC Nunes (3677_CR14) 2010; 5 R Tuteja (3677_CR19) 2007; 274 P Ward (3677_CR22) 2004; 5 R Vimee (3677_CR21) 2019; 16 K Haldar (3677_CR7) 2018; 16 AP Mnzava (3677_CR11) 2014; 108 SN Balaji (3677_CR3) 2020; 528 M Rug (3677_CR17) 2014; 124 G Siddiqui (3677_CR18) 2020; 188 BC Lin (3677_CR8) 2017; 2 S Batinovic (3677_CR4) 2017; 8 CA Moxon (3677_CR12) 2011; 154 3677_CR1 3677_CR2 S Das (3677_CR5) 2018; 379 RS Vijayan (3677_CR20) 2015; 58 |
References_xml | – volume: 15 start-page: 339 issue: 1 year: 2016 ident: 3677_CR16 publication-title: Malar J doi: 10.1186/s12936-016-1408-1 contributor: fullname: J Pousibet-Puerto – volume: 5 start-page: 79 year: 2004 ident: 3677_CR22 publication-title: BMC Genom doi: 10.1186/1471-2164-5-79 contributor: fullname: P Ward – volume: 108 start-page: 550 issue: 9 year: 2014 ident: 3677_CR11 publication-title: Trans R Soc Trop Med Hyg doi: 10.1093/trstmh/tru101 contributor: fullname: AP Mnzava – volume: 16 start-page: 156 issue: 3 year: 2018 ident: 3677_CR7 publication-title: Nat Rev Microbiol doi: 10.1038/nrmicro.2017.161 contributor: fullname: K Haldar – volume: 379 start-page: 1962 issue: 20 year: 2018 ident: 3677_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMc1713777 contributor: fullname: S Das – volume: 5 issue: 7 year: 2010 ident: 3677_CR14 publication-title: PLoS One doi: 10.1371/journal.pone.0011747 contributor: fullname: MC Nunes – volume: 58 start-page: 466 issue: 1 year: 2015 ident: 3677_CR20 publication-title: J Med Chem doi: 10.1021/jm501603h contributor: fullname: RS Vijayan – volume: 16 start-page: 417 issue: 4 year: 2019 ident: 3677_CR21 publication-title: Lett Drug Des Discov doi: 10.2174/1570180815666180727121200 contributor: fullname: R Vimee – volume: 8 start-page: 16044 year: 2017 ident: 3677_CR4 publication-title: Nat Commun doi: 10.1038/ncomms16044 contributor: fullname: S Batinovic – volume: 2 start-page: 6605 issue: 10 year: 2017 ident: 3677_CR8 publication-title: ACS Omega doi: 10.1021/acsomega.7b00997 contributor: fullname: BC Lin – ident: 3677_CR1 – volume: 528 start-page: 531 issue: 3 year: 2020 ident: 3677_CR3 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2020.05.154 contributor: fullname: SN Balaji – ident: 3677_CR15 – volume: 5 start-page: 848 issue: 6 year: 2020 ident: 3677_CR6 publication-title: Nat Microbiol doi: 10.1038/s41564-020-0702-4 contributor: fullname: H Davies – volume: 274 start-page: 4670 issue: 18 year: 2007 ident: 3677_CR19 publication-title: FEBS J doi: 10.1111/j.1742-4658.2007.05997.x contributor: fullname: R Tuteja – volume: 154 start-page: 670 issue: 6 year: 2011 ident: 3677_CR12 publication-title: Br J Haematol doi: 10.1111/j.1365-2141.2011.08755.x contributor: fullname: CA Moxon – ident: 3677_CR13 doi: 10.3390/tropicalmed4010026 – volume: 188 start-page: 774 issue: 5 year: 2020 ident: 3677_CR18 publication-title: Br J Haematol doi: 10.1111/bjh.16219 contributor: fullname: G Siddiqui – volume: 75 start-page: 217 year: 2017 ident: 3677_CR9 publication-title: Bioorg Chem doi: 10.1016/j.bioorg.2017.09.011 contributor: fullname: BC Lin – volume: 124 start-page: 3459 issue: 23 year: 2014 ident: 3677_CR17 publication-title: Blood doi: 10.1182/blood-2014-06-583054 contributor: fullname: M Rug – ident: 3677_CR2 doi: 10.1021/acsinfecdis.0c00724 – ident: 3677_CR10 doi: 10.1101/cshperspect.a025619 |
SSID | ssj0000515910 |
Score | 2.2842207 |
Snippet | The Plasmodium FIKK kinases are diverged from human kinases structurally. They harbour conserved ATP-binding domains that are non-homologous to other existing... |
SourceID | pubmedcentral proquest crossref pubmed springer |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 277 |
SubjectTerms | Agriculture Antimalarial activity Antimalarial agents Antiparasitic agents Binding Bioinformatics Biomaterials Biotechnology Calorimetry Cancer Research Chemistry Chemistry and Materials Science Enzyme inhibitors Heterocyclic compounds Kinases Libraries Life cycles Malaria Molecular interactions Organelles Organic compounds Original Original Article Parasites Plasmodium falciparum Proteomes Scaffolds Stem Cells Stoichiometry Substrates Survival Titration Titration calorimetry |
Title | Plasmodium falciparum FIKK 9.1 kinase modeling to screen and identify potent antimalarial agents from chemical library |
URI | https://link.springer.com/article/10.1007/s13205-023-03677-x https://www.ncbi.nlm.nih.gov/pubmed/37476548 https://www.proquest.com/docview/2839383892 https://www.proquest.com/docview/2841023811 https://pubmed.ncbi.nlm.nih.gov/PMC10354315 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB2x5QAXxDeBUhmJG3g3cZzYOVZtV0UVqBIgbU-R4w8R0SSrbha1_56xN9myVFy4RYklO5mx50087xngvXRCSKdTmhhuqBfoooXhmsYVz-MqdUlhPRv59Kv4spDHJ14mJx-5MKFoX1f1tL1spm39I9RWLhs9G-vEZuefj5I49RTubDaBCYLDP3L0QdE7K4IMAfM86UywxcCW2XDmUubr1VhKcfEWgnol6hRBtT9AfTc43UGcdwsn_9o9DUFp_hgeDWiSHG5G_QTu2fYpPBjJxqtn8Osc0XHTmXrdEKcufQH1FV7OP52dkWKakJ91i2GMhPNwsAfSdwTXEcxtiWoNqQOL192QZYfQusd7fd0ozIXRaYnypKwV8fwUogfZATL8FHoO3-cn345O6XDUAtUYonsqbeI1jpQT1kitLbNZYhhXmdWKOUyZChO7XHKjPLVHiEwbxVOnVVVlyrgsfQF7bdfaV0CsFSpJMehpKXjOC6m4UrHOuDAGwUoewYfxG5fLjaJGeaud7I1TonHKYJzyOoL90QzlMLtWJUKiAjNrWbAI3m0f47zwmx2qtd3at-FJwCNJBC83Vtt2N5o7Arljz20Dr7m9-wRdMWhvj64XwcfR9Lfj-vdrvP7_nt7AQxa81Rcd7sNef7W2b2GyMusDuH-4uLg4Pgj-_xvXSwgE |
link.rule.ids | 230,315,729,782,786,887,27933,27934,48344,48347,49649,49652,53800,53802 |
linkProvider | National Library of Medicine |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED_B9jD2wMeAERhgJN4gKI6d2HmsxkqrjgmJIu0tcv0BETSZ2hTBf8_ZTVqVwQO8RbGV2Oez786-388AL6UTQjrNYmq4iT1BV1wYruNkxvNkxhwtrEcjjz6Ki0v59szT5PAeCxOy3fsjybBSb8FuLPWJZimLcdUVIkbPcZ8XOUdd3h-Mp--Gm70Vf29JEYgIUo-UzkR62eFl_vyhXZt0zdG8ni_526FpsEXDO__Xi7twu_M9yWCtLPfghq2P4HDwedHxb9gjODjtL4DD5x60vLwP3z-glz1vTLWaE6e--UTsBT4Ox5MJKd5Q8rWq0RyScK8ONoe0DcH1CGNkompDqoAGdj_JVYMueovv2mquMKZG5SfKg7uWxONciO7oC0i3ufQAPg3PpqejuLuyIdZo6ttYWuq5kpQT1kitbWozalKuMqtV6jD0KkzicsmN8hAhITJtFGdOq9ksU8Zl7CHs1U1tHwGxVijK0HhqKTiOslRcqURnXBiDTk8ewat-0MqrNTNHueVg9lIuUcplkHL5I4KTflzLbpYuS3StCozQZZFG8GJTjFL2hyaqts3K1-E0-DU0guO1Gmx-xzAWyzHki0DuKMimgufu3i2pqy-Bw5smzLMQZBG87vVk266_d-Pxv1V_Dgej6fvz8nx8MXkCt9Kgdj558QT22sXKPoWbS7N61s2fX5hRFqo |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB5BV-Jx4LG8AgsYiRuEzcOJnWO1u2GrotVKLNLeItcPiKBJ1aYI_j0zaZKqLBwQtyi2Ens8tmfs-b4BeC2dENLp2A8NNz4RdPmZ4doPZjwNZrELM0to5NOP4uxSHp8QTc6A4m-j3fsryQ2mgViaquZwYdzhFvgWRxR0FsU-rsBC-GhF7tGxGB_B3nhy8T4fzlkoh0nWkhJEhJpORHTZYWf-_KHd_emK0Xk1dvK3C9R2X8rv_n-P7sGdziZl440S3YdrttqH2-PPy46Xw-7DzaM-MRw-92Dm1QP4fo7W97w25XrOnPpGAdpLfMwn0ynL3oXsa1nhNsnafDvYNNbUDNcp9J2ZqgwrW5Sw-8kWNTUV3zXlXKGvjZOCKQJ9rRjhX5juaA1Yd-j0ED7lJxdHp36XysHXaAI0vrQhcSgpJ6yRWtvIJqGJuEqsVpFDlywzgUslN4qgQ0Ik2igeO61ms0QZl8SPYFTVlX0CzFqhwhg3VS0FT3kmFVcq0AkXxqAxlHrwph_AYrFh7Ci23Mwk5QKlXLRSLn54cNCPcdHN3lWBJleGnrvMIg9eDcUoZbpMUZWt11SHh629E3rweKMSw-9i9NFSdAU9kDvKMlQgTu_dkqr80nJ7h0FM7ASJB297ndm26-_dePpv1V_CjfPjvPgwOZs-g1tRq3UU03gAo2a5ts_h-sqsX3RT6Rcn-h-D |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasmodium+falciparum+FIKK+9.1+kinase+modeling+to+screen+and+identify+potent+antimalarial+agents+from+chemical+library&rft.jtitle=3+Biotech&rft.au=Kumar%2C+D.+Anil&rft.au=Karjee%2C+Pallab&rft.au=Prasad%2C+M.+Rajendra&rft.au=Punniyamurthy%2C+Tharmalingam&rft.date=2023-08-01&rft.pub=Springer+International+Publishing&rft.issn=2190-572X&rft.eissn=2190-5738&rft.volume=13&rft.issue=8&rft_id=info:doi/10.1007%2Fs13205-023-03677-x&rft.externalDocID=10_1007_s13205_023_03677_x |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2190-572X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2190-572X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2190-572X&client=summon |